BBGBloomberg·3hBusiness
score-0.70
Galderma Vows to Address FDA Feedback on Relfydess as Botox Rival Awaits Path to US Market
Original
Galderma Shares Slump After FDA Turns Down Botox Rival Relfydess
“Strong negative framing with 'slumped,' 'turned down,' and emphasis on stock decline magnitude without mentioning reasons or future prospects.”